<DOC>
	<DOC>NCT02864953</DOC>
	<brief_summary>This study evaluates the use of the investigational drug CIRARA versus placebo in patients with a large hemispheric infarction.</brief_summary>
	<brief_title>CIRARA in Large Hemispheric Infarction Analyzing Modified Rankin Scale (mRS) and Mortality (CHARM)</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Brain Edema</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>1. A clinical diagnosis of acute ischemic stroke in the middle cerebral artery territory 2. A large lesion as defined by imaging 3. Time to the start of infusion of study drug ≤ 9 hours after time of symptom onset 4. Age ≥ 18 and ≤ 85 years 1. Commitment to decompressive craniectomy prior to enrollment 2. Treatment with intraarterial recombinant tissue plasminogen activator (rtPA) or by endovascular thrombectomy for clot disruption 3. Evidence of concurrent infarction in the contralateral hemisphere sufficiently serious so as to affect functional outcome 4. Clinical signs of herniation 5. Brain hemorrhage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>